However, due to the broad expression of CD47, treatment with CD47-targeting agents have caused significant anemia and thrombocytopenia in both preclinical studies and clinical trials,22–24 and higher therapeutic doses of CD47-targeting agents are needed to overcome the antigen sink and block CD47. Here, CD47 is linked to anemia (phenotype).